AC BioScience is a start-up biotech company located at the Biopôle life sciences campus near Lausanne and celebrates its seventh year of existence in March 2024. We are pioneering groundbreaking new therapies in immuno-oncology with a clinical focus on colorectal cancer (CRC).

Resulting from years of research into its two legacy oncology molecules, the company has achieved a breakthrough proprietary drug discovery with its new immunomodulating molecule ACB2112. The company was mindful of having secured a composition-of-matter patent together with an application patent in oncology for its new molecule ACB2112.


The Management consists of an experienced and well-balanced team with complementary skill-sets.

The Chairman and Chief Executive Officer is Andreas Schläpfer, a Swiss national, who has extensive experience in business strategy and global management. He holds a Master’s Degree in Economics from St. Gallen University, and has acted as an advisor to the International Trade Centre (UNCTAD/GATT). He spent more than three decades as a senior executive at the Nestlé Group (CEO in France, Russia, Thailand/Indochina) and as Global Business Head/Senior Vice President in charge of Nestlé's Infant Nutrition business.

Dr. Annette Ives is our newly appointed Chief Scientific Officer having held senior scientific responsibilities in our company since its inception. She has a Ph.D in Immunology and Infections from the University of Lausanne, and in her previous capacity was a Research Scientist and Project Manager with the Lausanne University Hospital (CHUV) and the WHO, respectively. She has published over 20 peer-reviewed articles. Dr Ives has both Australian and Swiss nationality.

Christine Evans joined us as our Head of Legal and Compliance. She is a former General Counsel and Chief Compliance Officer for multinational corporate and private investment mandates. She holds master’s in Economics and Juris Doctorate, Graduate School of International Studies and College of Law, University of Denver.

Jean-François Dufour-Lamartinie acts as our Clinical and Chief Medical Advisor, M.D., Oncology and Cancer Biology. Previously CMO at Hybrigenics and Head of clinical development at Bioalliance Pharma.

Board of Directors

The Co-founder Andreas Schläpfer is the Chairman of the Board and assumes the responsibilities of Chief Executive Officer.

Dr. Peter Hug joined the Board of Directors as a non-executive Director. A former Executive Vice President of Roche Pharma Partnering, he brings to the Board a wealth of experience in pharma licensing and business development.

Prof. Christian Auclair, Co-founder, Emeritus University Professor (exceptional class) and Doctor in Science (PharmD, PhD) was appointed Honorary Director following his resignation from the Board of Directors for health reasons.